Sarcopenia in patients with lung cancer: frequency, severity and implications - a mixed methods study

Sarcopenia in patients with lung cancer: frequency, severity and implications - a mixed methods study - SALEM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033002

Enrollment

120

Registered

2025-01-20

Start date

2024-09-10

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M62.5

Interventions

Group 1: Single-arm study among patients with pulmonary carcinoma starting cyclic therapy at the Department of Respiratory Medicine of the Nuremberg General Hospital.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with all forms of lung cancer who are being treated with chemotherapy, chemoimmunotherapy, radiochemotherapy (NSCLC) or oral tumor therapy with so-called "small molecules".

Exclusion criteria

Exclusion criteria: - Presence of a cardioverter defibrillator or pacemaker - Presence of psychological or physical impairments that do not allow study participation - language skills too poor to give informed consent

Design outcomes

Primary

Measure	Time frame
Prevalence: Presence of pre-/sarcopenia in patients with newly diagnosed lung cancer	—

Secondary

Measure	Time frame
- Expression of sarcopenia with regard to performance/body composition - Symptom burden, quality of life, health status and treatment-related toxicities - barriers and facilitators for the implementation of sarcopenia diagnostics and patient reported outcome measures	—

Countries

Germany

Contacts

Public ContactFelicitas Wening

Klinikum Nürnberg

felicitas.wening@klinikum-nuernberg.de+49 911 398 119132

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026